These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27576543)

  • 61. Clinical outcomes for cystic fibrosis patients with Pseudomonas aeruginosa cross-infections.
    Milczewska J; Wołkowicz T; Zacharczuk K; Mierzejewska E; Kwiatkowska M; Walicka-Serzysko K; Sands D
    Pediatr Pulmonol; 2020 Jan; 55(1):161-168. PubMed ID: 31556252
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
    Jensen T; Pedersen SS; Garne S; Heilmann C; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jun; 19(6):831-8. PubMed ID: 3301785
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
    Dasenbrook EC; Konstan MW; VanDevanter DR
    J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R; Parkins MD
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
    Elborn JS; Flume PA; Cohen F; Loutit J; VanDevanter DR
    J Cyst Fibros; 2016 Sep; 15(5):634-40. PubMed ID: 26935334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
    Fjaellegaard K; Sin MD; Browatzki A; Ulrik CS
    Chron Respir Dis; 2017 May; 14(2):174-186. PubMed ID: 27507832
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N; Frederiksen B; Pressler T
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
    Rognon A; Curti C; Montana M; Terme T; Rathelot P; Vanelle P
    Therapie; 2011; 66(6):481-91. PubMed ID: 22186073
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
    Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
    PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
    Barras MA; Serisier D; Hennig S; Jess K; Norris RL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Møller NE; Høiby N
    Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.